<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02890368</url>
  </required_header>
  <id_info>
    <org_study_id>TTI-621-02</org_study_id>
    <nct_id>NCT02890368</nct_id>
  </id_info>
  <brief_title>Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides</brief_title>
  <official_title>A Phase 1 Dose Escalation Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Percutaneously-Accessible Solid Tumors and Mycosis Fungoides</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Trillium Therapeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Trillium Therapeutics Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, open-label, phase 1 study conducted to test intratumoral injections of
      TTI-621 in subjects that have relapsed and refractory percutaneously accessible solid tumors
      or mycosis fungoides.

      The study will be performed in two different parts. Part 1 is the Dose Escalation phase and
      Part 2 is the Dose Expansion phase.

      The purpose of this study is to characterize the safety profile of TTI-621 and to determine
      the optimal dose and delivery schedule of TTI-621. In addition, the safety and antitumor
      activity of TTI-621 will be evaluated in combination with other anti-cancer agents or
      radiation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, open-label, phase 1 study conducted to test intratumoral injections of
      TTI-621 in patients that have relapsed and refractory percutaneously accessible solid tumors
      or mycosis fungoides.

      TTI-621 (SIRPα-IgG1 Fc) is a soluble recombinant fusion protein created by directly linking
      the sequences encoding the N-terminal CD47 binding domain of human SIRPα with the Fc domain
      of human immunoglobulin (IgG1). TTI-621 acts by binding human CD47 and preventing it from
      delivering an inhibitory &quot;do not eat&quot; (antiphagocytic) signal to macrophages.

      The study will be performed in two different parts: Dose Escalation and Dose Expansion.

      During the escalation part of the study, TTI-621 was studied at 3 different dose levels and
      at different dosing frequencies to characterize safety, tolerability, pharmacokinetics, and
      to determine the maximum tolerated dose (MTD).

      During the expansion part of the study, TTI-621 will be studied in an expanded group of
      patients at the maximum feasible dosing regimen determined in the escalation phase. After
      completion of their initial assigned therapy, subjects may receive continuation with TTI-621.
      The expansion phase will further define safety and characterize efficacy of TTI-621 alone and
      in combination with other anti-cancer therapies.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Optimal TTI-621 delivery regimen</measure>
    <time_frame>10 months</time_frame>
    <description>Defining the optimal TTI-621 delivery regimen in subjects with advanced percutaneously-accessible cancer</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency and severity of adverse events</measure>
    <time_frame>15 months</time_frame>
    <description>Safety of TTI-621 when given to subjects with relapsed and refractory percutaneously-accessible solid tumors and Mycosis Fungoides alone and in combination with other anti-cancer drugs or radiation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preliminary evidence of anti-tumor activity of TTI-621</measure>
    <time_frame>15 months</time_frame>
    <description>Preliminary evidence of anti-tumor activity of TTI-621 when given to subjects with relapsed and refractory percutaneously-accessible solid tumors and Mycosis Fungoides alone and in combination with other anti-cancer drugs or radiation</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Solid Tumors</condition>
  <condition>Mycosis Fungoides</condition>
  <condition>Melanoma</condition>
  <condition>Merkel-cell Carcinoma</condition>
  <condition>Squamous Cell Carcinoma</condition>
  <condition>Breast Carcinoma</condition>
  <condition>Human Papillomavirus-Related Malignant Neoplasm</condition>
  <condition>Soft Tissue Sarcoma</condition>
  <arm_group>
    <arm_group_label>TTI-621 Monotherapy Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TTI-621 Escalation phase of single or multiple doses of TTI-621 delivered by intratumoral injections (various dose cohorts).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TTI-621 Monotherapy (Single Lesion)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TTI-621 Single Lesion Injection Expansion Cohort</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TTI-621 Monotherapy (Multiple Lesions)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TTI-621 Multiple Lesion Injections Expansion Cohort</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TTI-621 + PD-1/PD-L1 Inhibitor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination Therapy Expansion Cohort of TTI-621 plus PD-1/PD-L1 Inhibitor</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TTI-621 + Pegylated Interferon-α2a</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination Therapy Expansion Cohort of TTI-621 plus Pegylated Interferon-α2a</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TTI-621 + T-Vec</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination Therapy Expansion Cohort of TTI-621 plus T-Vec</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TTI-621 + Radiation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination Therapy Expansion Cohort of TTI-621 plus Radiation Therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TTI-621 Monotherapy</intervention_name>
    <description>TTI-621 (SIRPα-IgG1 Fc) is a soluble recombinant fusion protein created by directly linking the sequences encoding the N-terminal CD47 binding domain of human SIRPα with the Fc domain of human immunoglobulin (IgG1). TTI-621 acts by binding human CD47 and preventing it from delivering an inhibitory &quot;do not eat&quot; (antiphagocytic) signal to macrophages.</description>
    <arm_group_label>TTI-621 Monotherapy Escalation</arm_group_label>
    <arm_group_label>TTI-621 Monotherapy (Single Lesion)</arm_group_label>
    <arm_group_label>TTI-621 Monotherapy (Multiple Lesions)</arm_group_label>
    <other_name>SIRPα-IgG1 Fc</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TTI-621 + PD-1/PD-L1 Inhibitor</intervention_name>
    <description>TTI-621 will be given in combination with one of the following programmed death-1 (PD-1) or programmed death-ligand-1 (PD-L1) inhibitors: nivolumab, pembrolizumab, durvalumab, avelumab, or atezolizumab administered on Day 1. Subjects in this cohort must have a cancer diagnosis for which a PD-1/PD-L1 inhibitor is approved by the FDA or listed in the National Comprehensive Cancer Network (NCCN) Guidelines.</description>
    <arm_group_label>TTI-621 + PD-1/PD-L1 Inhibitor</arm_group_label>
    <other_name>SIRPα-IgG1 Fc + PD-1/PD-L1 Inhibitor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TTI-621 + pegylated interferon-α2a</intervention_name>
    <description>TTI-621 will be given in combination with pegylated interferon-α2a. Subjects in this cohort must have a cancer diagnosis for which pegylated interferon-α2a is approved by the FDA or listed in the National Comprehensive Cancer Network (NCCN) Guidelines.</description>
    <arm_group_label>TTI-621 + Pegylated Interferon-α2a</arm_group_label>
    <other_name>SIRPα-IgG1 Fc + pegylated interferon-α2a</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>TTI-621 + T-Vec</intervention_name>
    <description>TTI-621 will be given in combination with talimogene laherparepvec (T-Vec). Subjects in this cohort must have unresectable melanoma.</description>
    <arm_group_label>TTI-621 + T-Vec</arm_group_label>
    <other_name>SIRPα-IgG1 Fc + talimogene laherparepvec</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>TTI-621 + radiation</intervention_name>
    <description>TTI-621 will be given following radiation to the target plasmacytoma. Subjects in this cohort must have relapsed multiple myeloma with bony or soft tissue plasmacytoma(s).</description>
    <arm_group_label>TTI-621 + Radiation</arm_group_label>
    <other_name>SIRPα-IgG1 Fc + radiation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically documented, injectable cancer lesion (limited to solid
             tumors and mycosis fungoides)

          -  Adequate renal function

          -  Adequate coagulation function

          -  Adequate hepatic function

          -  Disease that has progressed on standard therapy or for whom there is no other therapy
             option available

        Exclusion Criteria:

          -  Central nervous system involvement

          -  Significant cardiovascular disease

          -  Active autoimmune disease

          -  Active hepatitis B or C or a history of HIV infection

          -  Uncontrolled infection

          -  History of hemolytic anemia or bleeding diathesis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Penka Petrova, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Trillium Therapeutics Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Theresa Thompson</last_name>
    <email>theresa2@trilliumtherapeutics.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Penka Petrova, PhD</last_name>
    <phone>416-595-0627</phone>
    <phone_ext>234</phone_ext>
    <email>Penka@trilliumtherapeutics.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>City of Hope National Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jaemee Bautista</last_name>
      <phone>626-218-3033</phone>
      <email>jbautista@coh.org</email>
    </contact>
    <contact_backup>
      <last_name>Linda Lee</last_name>
      <phone>626-256-4673</phone>
      <phone_ext>89165</phone_ext>
      <email>Linlee@coh.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Knight Clinical Trials Information Line</last_name>
      <phone>503-494-1080</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15237</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sue McCann</last_name>
      <phone>412-864-3681</phone>
      <email>mccannsa@upmc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Washington - Seattle Cancer Care Alliance</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shahaan Smith</last_name>
      <phone>206-606-6448</phone>
      <email>sjsmith@seattlecca.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://clincancerres.aacrjournals.org/content/early/2016/11/16/1078-0432.CCR-16-1700.full-text.pdf</url>
    <description>TTI-621: a novel innate immune checkpoint inhibitor</description>
  </link>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 26, 2016</study_first_submitted>
  <study_first_submitted_qc>August 31, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 7, 2016</study_first_posted>
  <last_update_submitted>April 10, 2018</last_update_submitted>
  <last_update_submitted_qc>April 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CD47</keyword>
  <keyword>SIRPa</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>Checkpoint inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Mycoses</mesh_term>
    <mesh_term>Mycosis Fungoides</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Merkel Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Immunoglobulin G</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

